Renascience

Renascience Rule of 40

The Rule of 40 of Renascience (4889.T) as of Nov 19, 2026 is -568.93 %. In the previous year, Rule of 40 was -166.43 % — a change of 241.85% (lower).

Rule of 40

-568.93 %

YoY

241.85%

Last updated:

Rule of 40 of Renascience is 2026 -568.93 % . Rule of 40 of Renascience was 2025 -166.43 % . It decreases by 241.85% lower compared to the previous year.

The Renascience Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2021
150.34 JPY
Jan 1, 2022
-184.91 JPY
Jan 1, 2023
-359.90 JPY
Jan 1, 2024
-36.85 JPY
Jan 1, 2025
-166.43 JPY
Jan 1, 2026
-568.93 JPY
The Renascience Rule of 40 history
YEARRule of 40YoY
-568.93 %+241.85%
-166.43 %+351.68%
-36.85 %-89.76%
-359.90 %+94.64%
-184.91 %-222.99%
150.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Rule of 40 of Renascience is -568.93 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 Renascience since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Renascience

All Key Metrics — Renascience